論文 - 詳細
| RRC ID | 76355 |
|---|---|
| 著者 | Kawano M, Itonaga I, Iwasaki T, Tsuchiya H, Tsumura H. |
| タイトル | Anti-TGF-β antibody combined with dendritic cells produce antitumor effects in osteosarcoma. |
| ジャーナル | Clin Orthop Relat Res |
| Abstract |
BACKGROUND:We previously reported the combination of tumor cryotreatment with dendritic cells to promote antitumor immunity. The effect of the combination treatment with dendritic cells and antitransforming growth factor-β (anti-TGF-β) antibody on the elimination of regulatory T cells and the inhibition of tumor growth was investigated. QUESTIONS/PURPOSES:The effects of the combination treatment with dendritic cells and anti-TGF-β antibody on the enhancement of systemic immune responses and inhibition of metastatic tumor growth were investigated in a murine osteosarcoma (LM8) model. MATERIALS AND METHODS:To evaluate activation of the immune response, we established the following three groups of C3H mice (60 mice total): (1) excision only; (2) tumor excision and administration of anti-TGF-β antibody; and (3) tumor excision and administration of dendritic cells exposed to cryotreated tumor lysates with anti-TGF-β antibody. RESULTS:The mice that received dendritic cells exposed to cryotreated tumor lysates with anti-TGF-β antibody showed increased numbers of CD8(+) T lymphocytes, reduced regulatory T lymphocytes in the metastatic lesion, and inhibition of metastatic growth. The combined therapy group showed reduced numbers of regulatory T lymphocytes in the spleen and high serum interferon γ level. CONCLUSIONS:The control of the inhibitory condition induced by regulatory T cells is important to improve the suppression of the cytotoxic lymphocytes. Combining dendritic cells with anti-TGF-β antibody enhanced the systemic immune response. CLINICAL RELEVANCE:We suggest that our immunotherapy could be developed further to improve the treatment of osteosarcoma. |
| 巻・号 | 470(8) |
| ページ | 2288-94 |
| 公開日 | 2012-8-1 |
| DOI | 10.1007/s11999-012-2299-2 |
| PMID | 22415727 |
| PMC | PMC3392369 |
| MeSH | Animals Antibodies, Monoclonal / pharmacology* Bone Neoplasms / immunology Bone Neoplasms / therapy* CD8-Positive T-Lymphocytes / immunology Cancer Vaccines / administration & dosage* Combined Modality Therapy Dendritic Cells / immunology* Female Mice Mice, Inbred C3H Osteosarcoma / immunology Osteosarcoma / therapy* Transforming Growth Factor beta / immunology* Treatment Outcome Tumor Cells, Cultured Xenograft Model Antitumor Assays |
| IF | 4.329 |
| リソース情報 | |
| ヒト・動物細胞 | LM8(RCB1450) |